Ligritinib

Ligritinib
Clinical data
Other names	AB-801
Identifiers
	IUPAC name 6-[(7S)-3-[3-[5-(3-methyl-2-pyridinyl)-2-pyridinyl]-2H-pyrazolo[3,4-b]pyridin-5-yl]-6,7,8,9-tetrahydro-5H-benzo[7]annulen-7-yl]-3-oxa-6-azabicyclo[3.1.1]heptane;
CAS Number	3024588-48-2;
PubChem CID	170545987;
IUPHAR/BPS	14072;
ChemSpider	133328132;
UNII	8ZHG636DGC;
ChEMBL	ChEMBL6170680;
Chemical and physical data
Formula	C33H32N6O
Molar mass	528.660 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC1=C(N=CC=C1)C2=CN=C(C=C2)C3=C4C=C(C=NC4=NN3)C5=CC6=C(CC[C@@H](CC6)N7C8CC7COC8)C=C5;
	InChI InChI=InChI=1S/C33H32N6O/c1-20-3-2-12-34-31(20)24-8-11-30(35-16-24)32-29-14-25(17-36-33(29)38-37-32)23-5-4-21-6-9-26(10-7-22(21)13-23)39-27-15-28(39)19-40-18-27/h2-5,8,11-14,16-17,26-28H,6-7,9-10,15,18-19H2,1H3,(H,36,37,38)/t26-,27?,28?/m0/s1; Key:IANIKXYKEWAAKX-XWYKLZMASA-N;

Ligritinib is an investigational new drug that is being developed by Arcus Biosciences for the treatment of pancreatic adenocarcinoma, cholangiocarcinoma, and other solid tumors. It is an AXL receptor tyrosine kinase inhibitor.^[1]^[2]

References

↑ "Ligritinib". AdisInsight. Springer Nature Switzerland AG. Retrieved 3 July 2026.
↑ Miles DH, Lamani M, Paladugu SR, Qu S, Foley CN, Sharif EU, et al. (June 2025). "Discovery of AB801, a Potent and Selective Inhibitor of AXL Receptor Tyrosine Kinase for Use in Cancer Therapy". Journal of Medicinal Chemistry. 68 (11): 10663–10676. doi:10.1021/acs.jmedchem.5c00239. PMID 40407274. Compound 37